医学
活检
前列腺癌
置信区间
前列腺活检
放射科
前列腺
前瞻性队列研究
多参数磁共振成像
泌尿科
临床终点
核医学
融合
图像融合
回顾性队列研究
癌症检测
显著性差异
试验预测值
作者
Chen Huang,Lichen Jin,Yizhang Sun,Menglin Wu,Xuefeng Zhang,Xiaofeng Xu,Xuefeng He,Feng Qiu,Ximing Wang,Lingchuan Guo,Renpeng Huang,Jihui Li,Shengming Deng,Yuxin Lin,Xuedong Wei,Bin Zhang,Yuhua Huang
标识
DOI:10.1007/s00259-026-08181-x
摘要
PURPOSE: Multiparametric MRI (mpMRI)-ultrasound (US) fusion biopsy misses 8%-20% of clinically significant prostate cancer (csPCa), leaving a detection gap that prostate-specific membrane antigen (PSMA) PET/CT may help close. Whether incorporating PSMA into an MRI-US fusion platform improves csPCa detection has not been evaluated in a prospective paired design. We compared tri-modal PSMA PET/CT-MRI-US fusion biopsy with MRI-US fusion biopsy and systematic biopsy. METHODS: In this prospective, single-center, and paired diagnostic accuracy study (STARD 2015; ChiCTR2400089436), 308 biopsy-naive men underwent tri-modal fusion biopsy, MRI-US fusion biopsy, and systematic biopsy in a single session. The primary endpoint was the absolute difference in patient-level csPCa detection (International Society of Urological Pathology grade group ≥ 2) between tri-modal and MRI-US fusion biopsies. RESULTS: Tri-modal fusion detected 4.9% more csPCa than MRI-US fusion biopsy (95% confidence interval 2.4%-7.3%; P < 0.001; number needed to biopsy 20.5). The most significant gains were observed for PSMA-positive lesions < 10 mm (8.3%) and Prostate Imaging Reporting and Data System (PI-RADS) 4 lesions (5.8%), and this benefit persisted in multivariate generalized estimating equation models. The PSMA imaging-based risk score (area under the curve, 0.933) showed higher discrimination than the PRIMARY and molecular imaging PSMA scores. In a retrospective simulation using the test set, a risk-guided approach would have avoided approximately 42% of biopsies while missing 2.3% of csPCa. Limitations include the single-center design and the small test set. CONCLUSION: Tri-modal fusion was superior to MRI-US fusion biopsy in detecting csPCa, particularly in small PSMA-positive and PI-RADS 4 lesions. A PSMA-derived risk score enabled effective stratification, and in the test set, a simulated risk-guided approach showed potential for biopsy reduction. These findings require multicenter validation before clinical adoption. TRIAL REGISTRATION: ChiCTR2400089436 (Chinese Clinical Trial Registry, http://www.chictr.org.cn/ , registered 2024-09-09).
科研通智能强力驱动
Strongly Powered by AbleSci AI